Suppr超能文献

术后放化疗优于单纯术后化疗,适用于存在局限性 N2 淋巴结转移的鳞状细胞肺癌患者。

Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.

机构信息

Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, China.

Fujian Medical University, Fujian, 350122, China.

出版信息

BMC Cancer. 2019 Oct 30;19(1):1023. doi: 10.1186/s12885-019-6141-z.

Abstract

BACKGROUND

The aim of the present study was to assess the efficacy of postoperative chemoradiotherapy (POCRT) following surgery in non-small-cell lung cancer patients with N2 lymph node metastasis (N2-NSCLC).

METHODS

The clinical data of patients with N2-NSCLC treated with POCRT or postoperative chemotherapy (pCT) alone were retrospectively collected and reviewed. The overall survival (OS) rates were analyzed utilizing the Kaplan-Meier method and compared by the log-rank test. Cox regression analysis was used to determine factors significantly associated with survival. Propensity score matching (PSM) analysis was used to compensate for differences in baseline characteristics and OS was compared after matching.

RESULTS

Between 2004 and 2014, a total of 175 patients fulfilled the inclusion criteria, 60 of whom were treated with POCRT, while 115 were administered pCT. The 1, 3 and 5-year OS rates in the POCRT and pCT groups were 98.3 vs. 86.1%, 71.7 vs. 53.0% and 45.7 vs. 39.0%, respectively (P = 0.019). Compared with pCT, POCRT improved OS in patients with squamous cell subtype (P = 0.010), no lymphovascular invasion (P = 0.006), pN2a (P = 0.006) or total number of metastatic lymph nodes ≤7 (P = 0.016). After PSM, these survival differences between POCRT and pCT remained significant in patients with squamous cell lung cancer (P = 0.010).

CONCLUSIONS

POCRT following complete resection may be beneficial for patients with squamous cell lung cancer, particularly those with limited nodal involvement.

摘要

背景

本研究旨在评估非小细胞肺癌 N2 淋巴结转移(N2-NSCLC)患者手术后同步放化疗(POCRT)的疗效。

方法

回顾性收集并分析了接受 POCRT 或单纯术后化疗(pCT)治疗的 N2-NSCLC 患者的临床资料。采用 Kaplan-Meier 法分析总生存期(OS)率,并用对数秩检验进行比较。采用 Cox 回归分析确定与生存显著相关的因素。采用倾向评分匹配(PSM)分析来补偿基线特征的差异,并在匹配后比较 OS。

结果

2004 年至 2014 年期间,共有 175 例患者符合纳入标准,其中 60 例接受 POCRT 治疗,115 例接受 pCT 治疗。POCRT 组和 pCT 组的 1、3 和 5 年 OS 率分别为 98.3%比 86.1%、71.7%比 53.0%和 45.7%比 39.0%(P=0.019)。与 pCT 相比,POCRT 改善了鳞状细胞亚型(P=0.010)、无血管淋巴管侵犯(P=0.006)、pN2a(P=0.006)或转移淋巴结总数≤7(P=0.016)患者的 OS。经 PSM 后,POCRT 与 pCT 在鳞状细胞肺癌患者中的生存差异仍有统计学意义(P=0.010)。

结论

完全切除术后 POCRT 可能对鳞状细胞肺癌患者有益,特别是淋巴结受累有限的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633d/6820909/1a6de7846b59/12885_2019_6141_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验